We are pleased to share with you that we have entered into an exclusive strategic manufacturing collaboration with REGENXBIO Inc., a leading biotechnology company in gene therapy.  This partnership leverages WuXi’s industry-leading commercial biologics manufacturing and characterization capabilities, enabling REGENXBIO to develop top-quality manufacturing processes to advance its NAV® Technology gene therapies into the clinic and ultimately through to commercial markets.

Through this collaboration, REGENXBIO and WuXi will establish a proprietary production process for REGENXBIO’s NAV® Technology treatments designed to enable the rapid advancement of REGENXBIO’s and licensees’ therapeutic programs in WuXi’s 145,000 square-foot cGMP facility currently under construction in Philadelphia.  This facility is specially designed to accommodate gene therapy products that contain viral vectors such as REGENXBIO’s NAV Technology platform.  The partnership will combine REGENXBIO’s expertise in adeno-associated virus (AAV) process development with WuXi’s commercial manufacturing proficiency and established infrastructure.

This unique collaboration enables WuXi to work closely with REGENXBIO to provide an integrated solution to its gene therapy needs and to manufacture NAV Technology treatments at clinical and commercial scale to the highest quality standards.

 

Related Links:

  1.  Official press release
  2. WuXi to Build New Cell Therapy Manufacturing Facility for CAR-T Cells and Other Cancer Immunotherapies
  3. WuXi Breaks Ground on New Cell Therapy Manufacturing Facility in Philadelphia